论文部分内容阅读
目的观察美托洛尔联合胺碘酮用于冠心病心律失常治疗的疗效。方法 132例冠心病心律失常患者作为观察对象,按照不同治疗方法分为参照组和观察组,每组66例。参照组单纯予以胺碘酮治疗,观察组在参照组治疗基础上联合使用美托洛尔治疗。观察并比较两组临床疗效的差异性。结果治疗前两组收缩压(SBP)、舒张压(DBP)、心率(HR)比较差异均无统计学意义(P>0.05);治疗后观察组SBP、DBP、HR均优于参照组,差异均具有统计学意义(P<0.05)。观察组治疗总有效率为97.0%,高于参照组的81.8%,差异具有统计学意义(P<0.05)。观察组不良反应发生率为10.6%,与参照组的9.1%比较差异无统计学意义(P>0.05)。结论冠心病心律失常采用胺碘酮联合美托洛尔治疗,具有效果确切、安全有效的优点,值得临床借鉴和进一步使用推广。
Objective To observe the effect of metoprolol combined with amiodarone in the treatment of coronary heart disease. Methods A total of 132 patients with coronary heart disease and arrhythmia were divided into the reference group and the observation group according to different treatment methods, with 66 cases in each group. The reference group was treated with amiodarone. The observation group was treated with metoprolol combined with the reference group. To observe and compare the differences between the two groups in clinical efficacy. Results There were no significant differences in SBP, DBP and HR between the two groups before treatment (P> 0.05). SBP, DBP and HR in the observation group were better than those in the control group after treatment All were statistically significant (P <0.05). The total effective rate of observation group was 97.0%, higher than 81.8% of the reference group, the difference was statistically significant (P <0.05). The incidence of adverse reactions in the observation group was 10.6%, which was not significantly different from 9.1% in the reference group (P> 0.05). Conclusion Coronary heart disease arrhythmia with amiodarone combined with metoprolol treatment, with effective, safe and effective, merits the clinical reference and further use of the promotion.